Cancer Vaccines Competitive Landscape 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insight by DelveInsight | Merck and Moderna, ISA Pharma, PDS Biotech, Dendreon

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cancer Vaccines pipeline constitutes 250+ key companies continuously working towards developing 300+ Cancer Vaccines treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Cancer Vaccines Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cancer Vaccines Market.

The Cancer Vaccines Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cancer Vaccines Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Cancer Vaccines treatment therapies with a considerable amount of success over the years.

*
Cancer Vaccines companies working in the treatment market are Merck and Moderna, ISA Pharmaceuticals, PDS Biotechnology, Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech and others, are developing therapies for the Cancer Vaccines treatment

*
Emerging Cancer Vaccines therapies in the different phases of clinical trials are- mRNA-4157 (V940) + KEYTRUDA, Nelipepimut-S + Cemiplimab, PDS0101 + Pembrolizumab, DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others are expected to have a significant impact on the Cancer Vaccines market in the coming years.

*
In April 2025, Patients in England with advanced skin melanoma will gain accelerated access to a new vaccine from Scancell through a National Health Service (NHS) clinical trial. Developed by UK-based biotech Scancell, the off-the-shelf DNA vaccine, iSCIB1+, is designed to boost the immune system's ability to recognize cancer cells, thereby enhancing the effectiveness of immunotherapy treatments. Administered via a needle-free injection device, the treatment is given over a period of up to 85 weeks.

*
In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01.

*
In February 2025, In a Phase I investigator-initiated trial, all nine patients who received a personalized kidney cancer vaccine showed anti-cancer immune responses after tumor removal surgery. Conducted by researchers at the Dana-Farber Cancer Institute in the U.S., the study involved administering the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) post-surgery.

*
In August 2024, BioNTech initiated global clinical trials for BNT116, an mRNA-based vaccine designed as a potential therapy for non-small cell lung cancer (NSCLC), leveraging the same mRNA technology used in developing COVID-19 vaccines.

*
In July 2024, IO Biotech announced that results from a Phase II basket trial evaluating IO102-IO103 in combination with pembrolizumab will be shared at the ESMO Congress 2024, covering the full squamous cell carcinoma of the head and neck (SCCHN) cohort from the IOB-022/KN-D38 study.

*
In June 2024, LG Chem and AVEO Oncology have announced the enrollment of the first US patient in a Phase I clinical trial of LB-LR1109 (NCT06332755; LG project code LR19155), the first proprietary anti-cancer investigational drug candidate developed by LG Chem. The study includes participants with unresectable NSCLC, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma.

*
In June 2024, LG Chem and AVEO Oncology have announced the enrollment of the first US patient in a Phase I clinical trial of LB-LR1109 (NCT06332755; LG project code LR19155), LG Chem's first proprietary anti-cancer investigational drug. The study targets participants with unresectable NSCLC, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma.

Cancer Vaccines Overview

Cancer vaccines are medical treatments designed to stimulate the body's immune system to recognize and attack cancer cells. They can be preventive (reducing the risk of certain cancers, like HPV or hepatitis B vaccines) or therapeutic (helping treat existing cancers by targeting specific tumor antigens).

Get a Free Sample PDF Report to know more about Cancer Vaccines Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cancer-vaccines-competitive-landscape [https://www.delveinsight.com/report-store/cancer-vaccines-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Cancer Vaccines Drugs Under Different Phases of Clinical Development Include:

*
mRNA-4157 (V940) + KEYTRUDA: Merck and Moderna

*
Nelipepimut-S + Cemiplimab: ISA Pharmaceuticals

*
PDS0101 + Pembrolizumab: PDS Biotechnology

*
PROVENGE (sipuleucel-T): Dendreon Pharmaceuticals

*
CAN-2409: Candel Therapeutics

*
LB-LR1109: LG Chem and AVEO Oncology

*
DCVax-L: Northwest Biotherapeutics

*
IO102-IO103: IO Biotech

*
ITI-1000: Immunomic Therapeutics

*
EVX-01: Evaxion Biotech

*
CAN-2409: Candel Therapeutics

*
AST-301: Aston Sci

*
EVX-02: Evaxion Biotech

Cancer Vaccines Route of Administration

Cancer Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Cancer Vaccines Molecule Type

Cancer Vaccines Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Cancer Vaccines Pipeline Therapeutics Assessment

*
Cancer Vaccines Assessment by Product Type

*
Cancer Vaccines By Stage and Product Type

*
Cancer Vaccines Assessment by Route of Administration

*
Cancer Vaccines By Stage and Route of Administration

*
Cancer Vaccines Assessment by Molecule Type

*
Cancer Vaccines by Stage and Molecule Type

DelveInsight's Cancer Vaccines Report covers around 300+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Cancer Vaccines product details are provided in the report. Download the Cancer Vaccines pipeline report to learn more about the emerging Cancer Vaccines therapies [https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Cancer Vaccines Therapeutics Market include:

Key companies developing therapies for Cancer Vaccines are - GlaxoSmithKline PLC, Merck & Co. Inc., OSE Immunotherapeutics, Sanofi SA, Dendreon Pharmaceuticals LLC, Moderna Inc., Vaccitech Limited, Anixa Biosciences Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F Hoffmann-La Roche AG (Genentech), Providence Therapeutics, eTheRNA immunotherapies, and others.

Cancer Vaccines Pipeline Analysis:

The Cancer Vaccines pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Cancer Vaccines with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cancer Vaccines Treatment.

*
Cancer Vaccines key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Cancer Vaccines Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cancer Vaccines market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cancer Vaccines drugs and therapies [https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Cancer Vaccines Pipeline Market Drivers

*
Clinical trial data using personalized cancer vaccines are highly encouraging, cancer vaccines offer clinical benefits to patients with advanced metastatic disease, an attractive approach to synergize with currently available immune therapeutics strategies are some of the important factors that are fueling the Cancer Vaccines Market.

Cancer Vaccines Pipeline Market Barriers

*
However, hurdles in developing appropriate methods to identify, refine and test candidate therapies, high cost associated with the research and other factors are creating obstacles in the Cancer Vaccines Market growth.

Scope of Cancer Vaccines Pipeline Drug Insight

*
Coverage: Global

*
Key Cancer Vaccines Companies: Merck and Moderna, ISA Pharmaceuticals, PDS Biotechnology, Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others

*
Key Cancer Vaccines Therapies: mRNA-4157 (V940) + KEYTRUDA, Nelipepimut-S + Cemiplimab, PDS0101 + Pembrolizumab, DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others

*
Cancer Vaccines Therapeutic Assessment: Cancer Vaccines current marketed and Cancer Vaccines emerging therapies

*
Cancer Vaccines Market Dynamics: Cancer Vaccines market drivers and Cancer Vaccines market barriers

Request for Sample PDF Report for Cancer Vaccines Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Cancer Vaccines Report Introduction

2. Cancer Vaccines Executive Summary

3. Cancer Vaccines Overview

4. Cancer Vaccines- Analytical Perspective In-depth Commercial Assessment

5. Cancer Vaccines Pipeline Therapeutics

6. Cancer Vaccines Late Stage Products (Phase II/III)

7. Cancer Vaccines Mid Stage Products (Phase II)

8. Cancer Vaccines Early Stage Products (Phase I)

9. Cancer Vaccines Preclinical Stage Products

10. Cancer Vaccines Therapeutics Assessment

11. Cancer Vaccines Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cancer Vaccines Key Companies

14. Cancer Vaccines Key Products

15. Cancer Vaccines Unmet Needs

16 . Cancer Vaccines Market Drivers and Barriers

17. Cancer Vaccines Future Perspectives and Conclusion

18. Cancer Vaccines Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cancer-vaccines-competitive-landscape-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insight-by-delveinsight-merck-and-moderna-isa-pharma-pds-biotech-dendreon]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.